, 2012 ); although time to relapse was slower in the levomilnacipran ER group versus placebo, the treatment difference did not reach statistical significance because of the limited number of patients who relapsed.
← all excerpts
The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.
1
—
—